Brief treatment that combined suppression of the immunoproteasome with CTLA-immunoglobulin was able to prevent graft rejection for an extended period of time – up to half the lifespan of the mice in which the treatment was tested. The findings suggest that it may be possible to develop treatment regimens that reduce or even eliminate the need for constant immunosuppression in transplantees.